Scilex Holding Company

News & Events

Press Releases

In The Media

1. Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

   GlobeNewswire MAY 16, 2025 9:00 AM EDT
   PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “...
   READ ARTICLE

2. Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

   GlobeNewswire MAY 1, 2025 9:00 AM EDT
   PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “...
   READ ARTICLE

3. Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

   GlobeNewswire APR 30, 2025 1:46 PM EDT
   PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, ...
   READ ARTICLE

4. Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

   GlobeNewswire APR 22, 2025 9:00 AM EDT
   PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, ...
   READ ARTICLE

5. Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

   GlobeNewswire APR 16, 2025 2:12 PM EDT
   Gloperba ® is the first and only liquid oral version of the anti-gout medicine colchicin...
   READ ARTICLE

6. Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

   GlobeNewswire APR 15, 2025 9:00 AM EDT
   ELYXYB ® is a first-line treatment and the only FDA-approved, ready-to-use oral solution...
   READ ARTICLE

7. Scilex Holding Company Announces 1-for-35 Reverse Stock Split

   GlobeNewswire APR 11, 2025 9:00 AM EDT
   PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, ...
   READ ARTICLE

8. Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

   GlobeNewswire MAR 26, 2025 8:24 PM EDT
   PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, ...
   READ ARTICLE

9. Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

   GlobeNewswire MAR 10, 2025 9:00 AM EDT
   PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, ...
   READ ARTICLE

10. Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

    GlobeNewswire JAN 31, 2025 9:00 AM EST
    US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up peri...
    READ ARTICLE